April 18, 2016 5:47pm

Share pricing risk, lower volume and fatigue weigh on the sector

 

Do you care what happened today, you should … because it has implications to Tuesday's sector activity?   

Subscribe:  http://www.regmedinvestors.com/create-account   

 

 

 

There is one thing that everyone needs, and that's interpretation and translation of intelligence, not just news or information - we get too much!

  • To that end, I report a matrix of variables designed for investor’s consideration concerning the stem, cell and gene therapy regenerative medicine portfolio to track and monitor its pricing metric;

The takeaway is that investor need to decide what actions to take, or not take, based on their specific situation.

 

 

U.S. stocks closed higher Monday, with health care stocks among the top gainers but not “our” universe. All three major averages reversed an opening decline to close at their highest levels of the year so far. The Dow held about 106 points higher in the close, above the psychologically key 18,000 level for the first time since July 20, 2015.

The NASDAQ closed UP +21.80 or +0.44% to 4,960.02 and the DOW closed UP +106.70 or +0.60% to 18,004.16.

 

 

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector – the advance/decline line scenario of our 43 covered companies.

Monday, the stem, cell and gene therapy and regenerative medicine sector

  • Opened negative with an A/DL of 11/28 and 4 flats;
  • The mid-day turned positive with an A/DL of 23/18 with 2 flats;
  • The closing bell rang positive with A/DL of 25/17 with 1 flat

 

 

Henry’omics:

After Friday’s negative close, Monday opened negative and flipped to the positive at the mid-day and closed … positive.

  • In a world of high-frequency trading and day-trading speculation, it is hard for even the most experienced investors to stay … committed and rational, let alone be clear on whether to buy or hold or sell.

This is why I have seen positive hit and miss percentages in my Q1 recap and the last nine months of FY15.

  • While we are still not seeing the volume we would like, advances versus decliners have gotten to the point where upside rotations come quickly and depreciate even faster.

The question comes down to a measure of breadth which can be confirmed by my consistent advance/decline-line definitions.

  • The problem is the disruptive scenario of programs, machine speculation devastate alternating day’s pricing impact.

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

  • Monday traded near 13;
  • Friday traded below 14;
  • Thursday below 14;
  • Wednesday traded below 14;
  • Tuesday traded near 15;
  • Last, Monday traded above 16;

 

 

Out and about:

Caladrius Biosciences (CLBS) closed UP +$0.01 to a wholesome $0.68 after news of “an “iffy” CLI trial to proceed (?) with no partner in Japan” … http://www.regmedinvestors.com/articles/9029  … as I stated … Profile-raising is not persuasive!

Fibrocell (FCSC) closed DOWN -$0.13 to $2.56 on news of recessive dystrophic epidermolysis bullosa P1/2 trial … http://www.regmedinvestors.com/articles/9030 . As I opined a “butterfly” company – because their depth is just as fragile … SELL into any strength

StemCells (STEM) announced … cervical spine injury study shows encouraging results … http://www.regmedinvestors.com/articles/9028  … shares were UP 13.61 % to a whopping $0.263

 

 

Who was leading the declines – to of the bottom 5?

  • Kite Pharma (KITE) closed down -$2.21 to $47.93;
  • Intrexon (XON) -$0.97 to $36.99;
  • Mesoblast (MESO) -$0.38 to $9.08;
  • Fibrocell (FCSC) -$0.13 to $2.56;
  • ReNeuron (RENE.L) closed down -$0.12 to $3.00

 

 

Who was UP – top 5:

  • Spark Therapeutics (ONCE) closed up +$0.90 to $36.63;
  • Cellectis SA (CLLS) +40.78 to $29.08;
  • bluebird bio (BLUE) +$0.44 to $50.82;
  • Regenxbio (RGNX) +$0.40 to $11.99;
  • Avalanche (AAVL) closed UP +40.22 to $5.58

 

 

Most active sector stocks + and -:

  • Mesoblast (MESO) -4.02%;
  • Fibrocell (FCSC) -4.83%;
  • Kite Pharma (KITE) -4.41%;

Versus …

  • StemCells (STEM) +13.61;
  • Cytori (CYTX) +13.15%;
  • Avalanche (AAVL) +4.10%

 

 

Who was FLAT?

  • VistaGen (VSTA) at $8.00;

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.